Bellicum Pharmaceuticals Lands $55,000,000 Series C Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=74dd454c-1f4b-4e4e-bc2f-58404d436c49 - Date
8/27/2014 - Company Name
Bellicum Pharmaceuticals - Mailing Address
2130 West Holcombe Boulevard Houston, TX 77030 USA - Company Description
Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum utilize’s precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response. - Website
http://www.bellicum.com - Transaction Type
Venture Equity - Transaction Amount
$55,000,000 - Transaction Round
Series C - Proceeds Purposes
The funding will be used to expand the clinical evaluation of Bellicum’s stem cell transplant, chimeric antigen receptor (CAR) T cell and cancer vaccine product candidates in a variety of blood and solid tumor cancers, and in nonmalignant genetic diseases. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
